The AASLD now recommends semaglutide 2.4 mg/week for MASH with moderate-to-advanced fibrosis, based on FDA approval showing 63% achieved disease resolution versus 34% on placebo.
62.9% resolutionMASH resolution rate with semaglutide 2.4 mg/week at 72 weeks versus 34.3% placebo in the ESSENCE trial
What the researchers found
The AASLD updated its practice guidance to incorporate semaglutide for treating metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis. Semaglutide (Wegovy formulation, 2.4 mg/week subcutaneous) received accelerated FDA approval in August 2025 based on the ESSENCE trial, which showed:
- MASH resolution without worsening fibrosis: 62.9% vs 34.3% placebo
- Fibrosis improvement by ≥1 stage without worsening MASH: 37.0% vs 22.5% placebo
The guidance recommends semaglutide for MASH with F2-F3 fibrosis, with careful monitoring for patients with compensated cirrhosis. Lifestyle modification remains the cornerstone alongside drug therapy.
Why it matters
This is a landmark moment in liver disease treatment — semaglutide becomes the second FDA-approved drug for MASH (after resmetirom), addressing a condition that affects tens of millions of people and was previously untreatable. The AASLD guidance provides clinicians with the first official roadmap for patient selection, monitoring, and safety management.
The numbers in context
62.9% vs 34.3% MASH resolution · 37.0% vs 22.5% fibrosis improvement · 2.4 mg/week dose · 72 weeks · F2-F3 fibrosis indication · ALT reduction ≥17 U/L or ≥20% suggests response
How the study worked
AASLD clinical practice guidance update based on the ESSENCE phase 3 trial interim results. Provides recommendations for patient selection, treatment monitoring using non-invasive tests (VCTE, MRE, ELF, FIB-4), safety monitoring, and assessment of treatment response.
Who was studied
Adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced liver fibrosis (F2-F3)
What this study cannot tell us
Based on accelerated FDA approval with interim trial results — long-term outcomes data are still pending. Combination use with resmetirom has not been studied. Non-invasive tests cannot reliably predict individual histologic response. The guidance does not cover patients with decompensated cirrhosis or those with advanced fibrosis markers suggesting cirrhosis.
How to read the evidence
This is an official AASLD practice guidance based on a phase 3 randomized controlled trial (ESSENCE) with FDA approval. While the approval is accelerated (pending confirmatory data), the evidence supporting the recommendation is robust from a large clinical trial.
When this study was published
Published in 2025, this guidance reflects the most current evidence and FDA approval status for semaglutide in MASH treatment. The field is rapidly evolving.
The bigger picture
MASH is the fastest-growing cause of liver transplantation worldwide, and until 2024 there were no approved drugs. With resmetirom (approved 2024) and now semaglutide (2025), the treatment landscape has transformed. Semaglutide's additional metabolic benefits (weight loss, cardiovascular protection) make it particularly compelling for MASH patients, who typically have multiple metabolic comorbidities.
Questions still open
- Will combining semaglutide with resmetirom provide additive liver benefits?
- How long should semaglutide treatment continue for MASH — indefinitely or until specific endpoints are met?
- Will semaglutide's MASH indication expand to patients with compensated cirrhosis as more data emerge?
Common questions
Is semaglutide FDA-approved for fatty liver disease?
Who should consider semaglutide for liver disease?
Read the original research
Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance.
Hepatology (Baltimore, Md.)
Citation
Bansal, Meena B; Patton, Heather; Morgan, Timothy R; Carr, Rotonya M; Dranoff, Jonathan A; Allen, Alina M. (2025). Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance.. Hepatology (Baltimore, Md.). https://doi.org/10.1097/HEP.0000000000001608